Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
119 participants
INTERVENTIONAL
2008-01-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups
NCT01454011
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
NCT02111434
Efficacy, Pharmacokinetics and Safety of Testosterone
NCT01370369
Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism
NCT01160341
The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism
NCT02111473
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hypogonadism, treatment
77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
Testosterone enanthate (Sustanon 250 mg)
Twenty-eight patients were treated with testosterone enanthate (TE),
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)
twenty-five patients were treated with human chorionic gonadotropin (hCG)
Testosteron gel (Testojel 50 mg)
Twenty-four patients were treated with testosterone gel (TG).
Control group
42 healthy controls
Testosterone enanthate (Sustanon 250 mg)
Twenty-eight patients were treated with testosterone enanthate (TE),
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testosterone enanthate (Sustanon 250 mg)
Twenty-eight patients were treated with testosterone enanthate (TE),
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)
twenty-five patients were treated with human chorionic gonadotropin (hCG)
Testosteron gel (Testojel 50 mg)
Twenty-four patients were treated with testosterone gel (TG).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FSH and LH levels within or below the normal range,
* absence of a pituitary or hypothalamic mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH,
* normal smell test and normal karyotypes
Exclusion Criteria
* history of smoking,
* presence of bilateral anorchia,
* intellectual deficiency,
* diabetes mellitus,
* arterial hypertension or dyslipoproteinemia,
* medication of any kind and drug abuse. Because of possible confounding effects, patients with other hormone deficiencies were excluded.
Participants with iron, vitamin B12 or folate deficiency were also excluded.
18 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gulhane School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aydogan Aydogdu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aydogan Aydogdu, MD
Role: PRINCIPAL_INVESTIGATOR
Gulhane School of Medicine, Department of Endocrinology and Metabolism
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gulhane School of Medicine Dep. of Endocrine and Metabolism
Ankara, , Turkey (Türkiye)
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01052012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.